Margaret C. Taquey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Margaret C. Taquey has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Cailey Murphy
Medical University of South Carolina 1 Department of Biochemistry & Molecular Biology Charleston, South Carolina
17 shared publications - Channing J. Der
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
17 shared publications - Christabelle Rajesh
Medical University of South Carolina 4 Department of Biochemistry and Molecular Biology Charleston, South Carolina
17 shared publications - Christopher M. Counter
Department of Pharmacology & Cancer Biology, Duke University Medical Center
17 shared publications - David F. Kashatus
Department of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA
17 shared publications - Denis C. Guttridge
Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA
17 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
KPC cell lines utilize direct KRAS-PI3K–mediated signaling. A, Immunoblot of KRAS mutants expressed in hTERT-HPNE E6/E7 cell lines for 48 hours with doxycycline-induced KRAS expression. The image is representative of three independent experiments. B, Immunoblot of NIH “RASless” MEFs expressing BRAFV600E and KRASWT/G12D/R. The image is representative of three independent experiments. C, Immunoblot analysis from murine KPC cell lines after inhibition using the KRASG12D-specific inhibitor MRTX1133 at 20 nmol/L for 4 hours. Quantification of pAKTT308 after inhibition is shown underneath the blot. Blots are representative of two independent experiments. D, Immunoblot analysis of human KRASG12D PDAC cell lines after inhibition with the KRASG12D-specific inhibitor MRTX1133 at 20 nmol/L for 4 hours. Quantification of pAKTT308 after inhibition is shown underneath the blot. Data are representative of three independent experiments. E, Immunoblots with human KRASG12D PDX VMP PDAC cell lines after inhibition with the KRASG12D-specific inhibitor MRTX1133 at 20 nmol/L for 4 hours. Quantification of pAKTT308 after inhibition is shown underneath the blot. Data are representative of two independent experiments. F, Box-and-whisker plot with quantification of pAKTT308 in murine PDAC from C and human PDAC from D and E. P values were calculated using a Student t test comparing MRTX1133-treated cells with vehicle-treated cells. ***, P < 0.0002; ns, nonsignificant, P > 0.05. Error bars, mean ± SEM. Statistical tests were run using R 4.2.2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
KPC cell lines utilize direct KRAS-PI3K–mediated signaling. A, Immunoblot of KRAS mutants expressed in hTERT-HPNE E6/E7 cell lines for 48 hours with doxycycline-induced KRAS expression. The image is representative of three independent experiments. B, Immunoblot of NIH “RASless” MEFs expressing BRAFV600E and KRASWT/G12D/R. The image is representative of three independent experiments. C, Immunoblot analysis from murine KPC cell lines after inhibition using the KRASG12D-specific inhibitor MRTX1133 at 20 nmol/L for 4 hours. Quantification of pAKTT308 after inhibition is shown underneath the blot. Blots are representative of two independent experiments. D, Immunoblot analysis of human KRASG12D PDAC cell lines after inhibition with the KRASG12D-specific inhibitor MRTX1133 at 20 nmol/L for 4 hours. Quantification of pAKTT308 after inhibition is shown underneath the blot. Data are representative of three independent experiments. E, Immunoblots with human KRASG12D PDX VMP PDAC cell lines after inhibition with the KRASG12D-specific inhibitor MRTX1133 at 20 nmol/L for 4 hours. Quantification of pAKTT308 after inhibition is shown underneath the blot. Data are representative of two independent experiments. F, Box-and-whisker plot with quantification of pAKTT308 in murine PDAC from C and human PDAC from D and E. P values were calculated using a Student t test comparing MRTX1133-treated cells with vehicle-treated cells. ***, P < 0.0002; ns, nonsignificant, P > 0.05. Error bars, mean ± SEM. Statistical tests were run using R 4.2.2.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
Whole-body KrasLSL-G12R expression via Rosa26Cre-ERT2 drives heterogeneous hyperplasia in multiple tissues and increases endocrine pancreatic vacuole formation. A, Schematic of the KRRC. B, KRRC mice and littermate controls between 24 and 28 days received tamoxifen at 1 mg/10 g of body weight for 5 consecutive days via i.p. injections. C, Kaplan–Meier survival curves for KDRC mice: n = 11 (seven males and four females), Rosa26Cre-ER/LSL-EYFP control: n = 6 (three males and three females), KRRC mice: n = 5 (two males and three females), and KRRC controls: n = 2 (one male and one female). D, H&E staining of KRRC mouse tissues from the lung, spleen, liver, small intestine, and pancreas. A small tumor was detected in a single lobe of the lung in one KRRC mouse (black arrow). No major differences were observed in the spleen and liver between KRRC and control mice. Hyperplasia of the small intestine was observed in 2/5 KRRC mice (black arrow). KRRC mice also exhibited increased vacuole presence within exocrine cells of the pancreas (black arrow). Scale bar, 50 μm. E, Lung sections were immunostained for pErk1/2 and Ki-67 and false-colored. Images are representative of two Rosa26Cre-ERT2 control mice (one male and one female) and five KRRC mice (three males and two females). Scale bar, 100 μm. F, Box plot showing the average intensity of pErk1/2 in Rosa26CreERT2/+ and KrasLSL-G12R/+;Rosa26Cre-ERT2/+ mice. Five fields of view were taken from each lung. P values were calculated using a Student t test comparing control mice with G12R. *, P < 0.05. Error bars, mean ± SEM. G, Box plot showing the average intensity of Ki-67 in the pancreas of Rosa26Cre-ERT2/+ and KrasLSL-G12R/+;Rosa26Cre-ERT2/+ mice. Five FOV from each mouse (two control and three KRRC). P values were calculated using a Student t test comparing control mice with KRRC. Error bars, mean ± SEM. All statistical tests were run using R 4.2.2. ns, nonsignificant. Created in BioRender. Burge, R. (2025) https://BioRender.com/jv6j4ns.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
Whole-body KrasLSL-G12R expression via Rosa26Cre-ERT2 drives heterogeneous hyperplasia in multiple tissues and increases endocrine pancreatic vacuole formation. A, Schematic of the KRRC. B, KRRC mice and littermate controls between 24 and 28 days received tamoxifen at 1 mg/10 g of body weight for 5 consecutive days via i.p. injections. C, Kaplan–Meier survival curves for KDRC mice: n = 11 (seven males and four females), Rosa26Cre-ER/LSL-EYFP control: n = 6 (three males and three females), KRRC mice: n = 5 (two males and three females), and KRRC controls: n = 2 (one male and one female). D, H&E staining of KRRC mouse tissues from the lung, spleen, liver, small intestine, and pancreas. A small tumor was detected in a single lobe of the lung in one KRRC mouse (black arrow). No major differences were observed in the spleen and liver between KRRC and control mice. Hyperplasia of the small intestine was observed in 2/5 KRRC mice (black arrow). KRRC mice also exhibited increased vacuole presence within exocrine cells of the pancreas (black arrow). Scale bar, 50 μm. E, Lung sections were immunostained for pErk1/2 and Ki-67 and false-colored. Images are representative of two Rosa26Cre-ERT2 control mice (one male and one female) and five KRRC mice (three males and two females). Scale bar, 100 μm. F, Box plot showing the average intensity of pErk1/2 in Rosa26CreERT2/+ and KrasLSL-G12R/+;Rosa26Cre-ERT2/+ mice. Five fields of view were taken from each lung. P values were calculated using a Student t test comparing control mice with G12R. *, P < 0.05. Error bars, mean ± SEM. G, Box plot showing the average intensity of Ki-67 in the pancreas of Rosa26Cre-ERT2/+ and KrasLSL-G12R/+;Rosa26Cre-ERT2/+ mice. Five FOV from each mouse (two control and three KRRC). P values were calculated using a Student t test comparing control mice with KRRC. Error bars, mean ± SEM. All statistical tests were run using R 4.2.2. ns, nonsignificant. Created in BioRender. Burge, R. (2025) https://BioRender.com/jv6j4ns.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
Pancreas-specific coexpression of KrasLSL-G12D/+;Trp53LSL-R172H/+, but not KrasLSL-G12R/+;Trp53LSL-R172H/+, drives invasive PDAC. A, Schematic of the generation of the KrasLSL-G12R allele. NEO, neomycin resistance cassette and was used as a selectable marker. B, Schematic of the KrasLSL-G12R/+;Trp53LSL-R172H/+;p48Cre-ERTM mouse model (KP48). C, Mice and littermate controls (24–28 days old) received tamoxifen (1 mg/10 g body weight) via i.p. injection for five consecutive days. D, Kaplan–Meier survival curves for controls (n = 26), KDP48 (n = 26), and KRP48 (n = 20) mice. E, Gross images of the pancreas (panc) and spleen (spl). Pancreas sections were additionally stained with H&E, immunostained for pErk1/2 and Kras, and stained with Masson’s trichrome. Images are representative of six mice from each cohort (three male; three female). Immunostained markers were false-colored brown for visualization. H&E images were analyzed by a veterinary pathologist. Scale bar, 100 μm. Created in BioRender. Burge, R. (2025) https://BioRender.com/jv6j4ns.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
Pancreas-specific coexpression of KrasLSL-G12D/+;Trp53LSL-R172H/+, but not KrasLSL-G12R/+;Trp53LSL-R172H/+, drives invasive PDAC. A, Schematic of the generation of the KrasLSL-G12R allele. NEO, neomycin resistance cassette and was used as a selectable marker. B, Schematic of the KrasLSL-G12R/+;Trp53LSL-R172H/+;p48Cre-ERTM mouse model (KP48). C, Mice and littermate controls (24–28 days old) received tamoxifen (1 mg/10 g body weight) via i.p. injection for five consecutive days. D, Kaplan–Meier survival curves for controls (n = 26), KDP48 (n = 26), and KRP48 (n = 20) mice. E, Gross images of the pancreas (panc) and spleen (spl). Pancreas sections were additionally stained with H&E, immunostained for pErk1/2 and Kras, and stained with Masson’s trichrome. Images are representative of six mice from each cohort (three male; three female). Immunostained markers were false-colored brown for visualization. H&E images were analyzed by a veterinary pathologist. Scale bar, 100 μm. Created in BioRender. Burge, R. (2025) https://BioRender.com/jv6j4ns.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S7 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
KRASG12R-mutant cell lines have reduced migration.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S7 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
KRASG12R-mutant cell lines have reduced migration.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
KrasLSL-G12D/+;Trp53LSL-R172H/+;p48LSL-Cre-ERTM promotes PDAC and liver metastases whereas KrasLSL-G12R/+;Trp53LSL-R172H/+;p48LSL-Cre-ERTM drives inflammation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
KrasLSL-G12D/+;Trp53LSL-R172H/+;p48LSL-Cre-ERTM promotes PDAC and liver metastases whereas KrasLSL-G12R/+;Trp53LSL-R172H/+;p48LSL-Cre-ERTM drives inflammation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
Engineering a KrasLSL-G12R/+ murine model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
Engineering a KrasLSL-G12R/+ murine model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
Full body KrasLSL-G12D;Rosa26Cre-ER/LSL-EYFP increases endocrine pancreatic vacuoles and drives changes in the lung and spleen.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
Full body KrasLSL-G12D;Rosa26Cre-ER/LSL-EYFP increases endocrine pancreatic vacuoles and drives changes in the lung and spleen.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S5 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
The frequency of co-mutations in tumor suppressor genes is not dependent on KRAS mutation status in human pancreatic cancer patients in the AACR Project GENIE dataset.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S5 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
The frequency of co-mutations in tumor suppressor genes is not dependent on KRAS mutation status in human pancreatic cancer patients in the AACR Project GENIE dataset.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 7 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
KRASG12R-mutant cell lines exhibit reduced migration and collagen deposition. A, Representative images of migration assays from a panel of KRASG12D and KRASG12R PDAC cell lines. Scale bar, 50 μm. B, Box-and-whisker plot showing quantification of migration assays from A. Mean values are plotted, with each data point representing the percentage of area migrated from at least three technical replicates from three separate experiments for each cell line. C, Number of metastatic sites in each patient across indicated KRAS mutations. D, Schematic of the rapid autopsy program and how total liver involvement is examined for invasion. E, Liver involvement of metastatic lesions. For C and E, mean values are plotted, with each data point represented by a circle. KRASG12D, n = 37; KRASG12R, n = 17. F, Significant Molecular Signatures Database Gene Ontology pathway collagen containing extracellular matrix genes and all collagen genes from GSEA comparing PDX KRASG12D tumors with KRASG12R tumors. NES and P values are listed by corresponding pathways. G, Representative brightfield and polarized light images of collagen structures of KRASG12D/R using PSR. Polarized light images are representative and at 20× magnification. Scale bar, 300 μm. H, Box-and-whisker plot showing quantification of PSR in KRASG12D/R resected tumor samples (n = 3). Mean values are plotted, with each data point representing the percentage of the area of collagen normalized to the total tumor size. All P values were calculated using the Student t test comparing G12D and G12R. *, P < 0.05; ****, P < 0.00001; ns, nonsignificant, P > 0.05. Error bars, mean ± SEM.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
KRASG12R-mutant cell lines exhibit reduced migration and collagen deposition. A, Representative images of migration assays from a panel of KRASG12D and KRASG12R PDAC cell lines. Scale bar, 50 μm. B, Box-and-whisker plot showing quantification of migration assays from A. Mean values are plotted, with each data point representing the percentage of area migrated from at least three technical replicates from three separate experiments for each cell line. C, Number of metastatic sites in each patient across indicated KRAS mutations. D, Schematic of the rapid autopsy program and how total liver involvement is examined for invasion. E, Liver involvement of metastatic lesions. For C and E, mean values are plotted, with each data point represented by a circle. KRASG12D, n = 37; KRASG12R, n = 17. F, Significant Molecular Signatures Database Gene Ontology pathway collagen containing extracellular matrix genes and all collagen genes from GSEA comparing PDX KRASG12D tumors with KRASG12R tumors. NES and P values are listed by corresponding pathways. G, Representative brightfield and polarized light images of collagen structures of KRASG12D/R using PSR. Polarized light images are representative and at 20× magnification. Scale bar, 300 μm. H, Box-and-whisker plot showing quantification of PSR in KRASG12D/R resected tumor samples (n = 3). Mean values are plotted, with each data point representing the percentage of the area of collagen normalized to the total tumor size. All P values were calculated using the Student t test comparing G12D and G12R. *, P < 0.05; ****, P < 0.00001; ns, nonsignificant, P > 0.05. Error bars, mean ± SEM.